Gynecology Cases Performed Successfully with FMX314 Surgical Platform

20 Jun, 2016, 05:40 ET from Fortimedix Surgical B.V.

NUTH, The Netherlands, June 20, 2016 /PRNewswire/ --

Following successful use of FMX314 in general surgery, the innovative platform for single-port laparoscopy has now been employed in several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform for other surgical applications.

     (Logo: http://photos.prnewswire.com/prnh/20160324/348000LOGO )

FMX314 is the world's first single-port surgery solution that is compatible with a standard 15mm laparoscopic trocar, promising fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis. A procedure with the platform closely mimics conventional, multi-port laparoscopy, which makes FMX314 easy to use.

Market introduction of FMX314 in the United States for abdominal laparoscopic surgery is expected in the fourth quarter of this year, followed by commercial launch in Europe.

Caution: The FMX314 Surgical Platform is an investigational device and not available for sale.

About Fortimedix Surgical 

Fortimedix Surgical is a fast growing medical device product definition company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a US subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to continuing the evolution of minimally invasive surgery by driving technological innovation across surgical specialties to improve the quality of life of patients throughout the world.

For more information, please visit http://www.fortimedixsurgical.com

Forward-Looking Statements 

Certain statements herein include "forward-looking" statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances. 

###

Note for Editors

Digital press release available at: http://www.fortimedix.com/who-we-are/news-archive-article-fmx314-across-surgical-specialties


SOURCE Fortimedix Surgical B.V.